These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 14675099)

  • 21. Limited fibrin specificity of tissue-type plasminogen activator and its potential link to bleeding.
    Weitz JI
    J Vasc Interv Radiol; 1995; 6(6 Pt 2 Suppl):19S-23S. PubMed ID: 8770837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasmin (Human) Administration in Acute Middle Cerebral Artery Ischemic Stroke: Phase 1/2a, Open-Label, Dose-Escalation, Safety Study.
    Mitchell PJ; Yan B; Brozman M; Ribo M; Marder V; Courtney KL; Saver JL;
    J Stroke Cerebrovasc Dis; 2017 Feb; 26(2):308-320. PubMed ID: 27793534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Locally delivered plasmin: why should it be superior to plasminogen activators for direct thrombolysis?
    Novokhatny VV; Jesmok GJ; Landskroner KA; Marder VJ; Zimmerman TP
    Trends Pharmacol Sci; 2004 Feb; 25(2):72-5. PubMed ID: 15102492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pre-clinical studies of plasmin: superior benefit-to-risk ratio of plasmin compared to tissue plasminogen activator.
    Marder VJ
    Thromb Res; 2008; 122 Suppl 3(Suppl 3):S9-S15. PubMed ID: 18722003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New anticoagulants in ischemic heart disease.
    Verheugt FW
    Presse Med; 2005 Oct; 34(18):1325-9. PubMed ID: 16269997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of a synthetic antithrombin III-binding pentasaccharide and standard heparin as an adjunct to coronary thrombolysis.
    Pislaru SV; Pislaru C; Zhu X; Arnout J; Stassen T; Vanhove P; Herbert JM; Meuleman DG; Van de Werf F
    Thromb Haemost; 1998 Jun; 79(6):1130-5. PubMed ID: 9657437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ischaemic stroke: acute-phase drug therapy. Mostly aspirin and heparin.
    Prescrire Int; 2005 Aug; 14(78):146-52. PubMed ID: 16106599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Arterial antithrombotic effects of aspirin, heparin, enoxaparin and clopidogrel alone, or in combination, in the rat.
    Daykin HJ; Sturgeon SA; Jones C; Wright CE
    Thromb Res; 2006; 118(6):755-62. PubMed ID: 16410020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microparticle-linked tissue factor activity and increased thrombin activity play a potential role in fibrinolysis failure in ST-segment elevation myocardial infarction.
    Huisse MG; Ajzenberg N; Feldman L; Guillin MC; Steg PG
    Thromb Haemost; 2009 Apr; 101(4):734-40. PubMed ID: 19350119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
    Mruk JS; Zoldhelyi P; Webster MW; Heras M; Grill DE; Holmes DR; Fuster V; Chesebro JH
    Circulation; 1996 Feb; 93(4):792-9. PubMed ID: 8641009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and The International Study Group.
    Maggioni AP; Franzosi MG; Santoro E; White H; Van de Werf F; Tognoni G
    N Engl J Med; 1992 Jul; 327(1):1-6. PubMed ID: 1598096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
    Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM
    JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thrombolytic therapy causes an increase in vascular permeability that is reversed by 1-deamino-8-D-vasopressin.
    Rudd MA; Johnstone MT; Rabbani LE; George D; Ware JA; Loscalzo J
    Circulation; 1991 Dec; 84(6):2568-73. PubMed ID: 1835680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute myocardial infarction-failed thrombolysis followed by severe upper gastrointestinal bleeding.
    Remskar M; Mozina H; Noc M; Zorman D; Stepec S
    Resuscitation; 1999 Aug; 41(3):282-3. PubMed ID: 10507717
    [No Abstract]   [Full Text] [Related]  

  • 35. Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits.
    Gardell SJ; Ramjit DR; Stabilito II; Fujita T; Lynch JJ; Cuca GC; Jain D; Wang SP; Tung JS; Mark GE
    Circulation; 1991 Jul; 84(1):244-53. PubMed ID: 1905593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs.
    Jun L; Arnout J; Vanhove P; Dol F; Lormeau JC; Herbert JM; Collen D; Van de Werf F
    Coron Artery Dis; 1995 Mar; 6(3):257-63. PubMed ID: 7788040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of degradation of antithrombin III by tissue-type plasminogen activator or plasmin.
    Torr-Brown SR; Nachowiak D; Fujii S; Sobel BE
    Coron Artery Dis; 1994 Jul; 5(7):625-31. PubMed ID: 7952425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fibrinogen level as a surrogate for the outcome of thrombolytic therapy using tissue plasminogen activator for acute lower extremity intravascular thrombosis.
    Skeik N; Gits CC; Ehrenwald E; Cragg AH
    Vasc Endovascular Surg; 2013 Oct; 47(7):519-23. PubMed ID: 23899656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of local thrombolytic efficacy of plasmin and rt-PA in an in-vitro flow system; a pilot study.
    Bizjak N; Bajd F; Vidmar J; Blinc A; Marder VJ; Novokhatny V; Serša I
    Blood Coagul Fibrinolysis; 2013 Oct; 24(7):711-4. PubMed ID: 23751605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators.
    Cannon CP; Gibson CM; McCabe CH; Adgey AA; Schweiger MJ; Sequeira RF; Grollier G; Giugliano RP; Frey M; Mueller HS; Steingart RM; Weaver WD; Van de Werf F; Braunwald E
    Circulation; 1998 Dec 22-29; 98(25):2805-14. PubMed ID: 9860780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.